Albertsons Companies, Inc.(ACI)Earnings, Financials & Key Ratios

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three Alzheimer's disease (AD) cohorts in ABATE Anti-Abeta antibody dose-response demonstrated with antibodies detected at all dose levels in cohorts AD1-3 Ongoing AD4 cohort includes additional adjuvant designed to enhance ACI-24 responses Lausanne, Switzerland, June 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim data from the first three cohorts (AD1, AD2 & AD3) of 74 patients with prodromal Alzheimer's disease (AD) in the Phase 1b/2 ABATE trial following 12 months of treatment with ACI-24 anti-amyloid beta (Abeta) active immunotherapy. In the trial to date, ACI-24 has been generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities-edema (ARIA-E).

For investors looking to build a defensive hedge within a diversified portfolio, these attractively valued consumer food stocks may deserve a closer look.

Albertsons has launched a new integration with commerce intelligence platform Criteo. The partnership, announced Thursday (June 25) by the grocery giant's retail media arm Albertsons Media Collective, is designed to bring product discovery into Albertsons artificial intelligence-powered conversational search.

Investors need to pay close attention to ACIW stock based on the movements in the options market lately.

[url="]Albertsons Media Collective[/url], the retail media arm for [url="]Albertsons Companies[/url], Inc. (NYSE: ACI), today announced a new integration with